Title : LCPT once-daily extended-release tacrolimus tablets versus twice-daily capsules: a pooled analysis of two phase 3 trials in important de novo and stable kidney transplant recipient subgroups.

Pub. Date : 2016 May

PMID : 26953629






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 A novel once-daily formulation of tacrolimus (LCPT) has demonstrated noninferiority, similar safety, improved bioavailability, a consistent concentration time profile, and less peak and peak-trough fluctuations vs. tacrolimus twice-daily (Tac BID). Tacrolimus BH3 interacting domain death agonist Homo sapiens